All News
Good News from ACR17 - Gout
The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
Read Article
MTX Doubles Hepatotoxicity Risk in Psoriasis Patients
A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when
Read Article
Crescendo ACR Presentations
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov.
Read Article
High Volume Lyme Disease Reporting in Low Incidence Arkansas
Even though Arkansas lies on the edge of the geographic range of the principal Lyme disease tick vector, Ixodes scapularis, the risk for Lyme infection is low, and no confirmed Lyme disease cases were reported in Arkansas during 2008–2014 (1)
Read Article
The RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read Article
Isolated SS-B Not Associated with Connective Tissue Disease
A one-year prospective study of 624 patients undergoing autoantibody testing for anti-SS-A and/or anti-SS-B autoantibodies finds that isolated anti-SS-B autoantibodies was not associated with features or the diagnosis of any specific connective tissue diseases (CTD).
Read Article
Rituximab Efficacy in IgG4 Related Disease
PLOS reports greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD).
Read Article
Do Rheumatologists Use ACR/EULAR Guidance on Rheumatoid Arthritis? “Live Vote” Results
The June 2017 RheumNow “Live Vote” surveyed US and non-US rheumatologists and patients about how they diagnose and treat rheumatoid arthritis (RA) and whether they rely on newer diagnostic criteria and management guidelines propagated by the American College of Rheumatology (ACR).
Read Article
Canakinumab Reduces CV Outcomes in High Risk Patients
The results of a randomized, double-blind trial have shown that canakinumab (CAN), an interleukin-1β inhibitor, given as 150 mg every 3 months, resulted in a significantly lower rate of recurrent cardiovascular events (in high-risk CV patients), independent of lipid-level lowering. The results of the CANTOS studywere simultaneously published in NEJM, Lancet and were presented at the European Society of Cardiology meeting in Barcelona.
Read Article
How Much Testing is Enough?
I saw a patient this past week with new onset polyarthralgia, which led me to ponder how my fellow rheumatologists would utilize laboratory testing in such a patient.
Read Article
The RheumNow Week in Review – 11 August 2017
The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.
Read Article
The RheumNow Week in Review – 4 August 2017
Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com.
Read Article
Pediatric Consensus on Comorbidity Assessments
Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.
Read Article
Lupus Hospitalizations are Common
Patients with systemic lupus erythematosus (SLE) incur substantial morbidity and complications that may lead to hospitalizations and increased cost of lupus care. Researchers from the University Health Network in Toronto have published a review of SLE hospitalizations showing thta while comm
Read ArticleThe RheumNow Week in Review – 21 July 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com:
Read Article
Lymphopenia and Steroids Increase the Risk of Pneumocystis Jiroveci in Systemic Rheumatic Diseases
It is well-known that patients with systemic autoimmune diseases are at risk for Pneumocystis jirovecii pneumonia (PJP) and although infrequent, it carries a high mortality. A new study shows lymphopenia and steroid use increases the risk of PJP.
Read Article
Potential Reasons Why Osteoarthritis Preferentially Affects Women
Researchers from Augusta University have examined exosomes from patients with knee osteoarthritis (OA) to enhance our molecular understanding of the pathogenesis of OA. (Citation source http://buff.ly/2tuDZ3v)
Read Article
Bone Turnover Markers in Practice: A Guide for the Rheumatologist
Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.
Read Article
NLRP3 Activation in Still's Disease
Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.
Read Article
The RheumNow Week in Review – 5 May 2017
Dr Jack Cush reviews highlights from the news last week on RheumNow.com:
Read Article
